BioSpace News Archive

Business

Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022Company to host a Conference Call & Webcast at 8:00 a.m. ET

Trevena, Inc. today announced that it will release its financial results for the third quarter ended September 30, 2022, prior to the market open on Wednesday, November 9, 2022.

November 7, 2022
·
2 min read
Genetown

TScan Therapeutics Announces Upcoming Virtual Investor Event

TScan Therapeutics, Inc. today announced that management will host a virtual investor event on Monday, November 14, 2022 at 5:00 p.m. ET.

November 7, 2022
·
1 min read
FDA

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Corp. today reports the U.S. Food and Drug Administration’s (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX®2-73 (blarcamesine) for the treatment of Fragile X syndrome.

November 7, 2022
·
5 min read
BioForest

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

Athira Pharma, Inc. today announced that it will be presenting preclinical data demonstrating the therapeutic potential of enhancing the HGF/MET neurotrophic system at Neuroscience 2022.

November 7, 2022
·
5 min read
Genetown

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Talaris Therapeutics, Inc. presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.

November 7, 2022
·
4 min read
Drug Development

Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT

Kamada today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

November 7, 2022
·
6 min read
Business

Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights.

November 7, 2022
·
15 min read
Business

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Entrada Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates.

November 7, 2022
·
8 min read
Business

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today reported financial results and key operational progress updates for the third quarter ended September 30, 2022.

November 7, 2022
·
8 min read
Deals

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Avalo Therapeutics, Inc., announced it entered into a purchase agreement to sell its economic rights to future payments for previously out-licensed assets including AVTX-007, AVTX-501, and AVTX-611 to ES Therapeutics, LLC in exchange for $5.0 million.

November 7, 2022
·
5 min read